Good Predictions: FDA Encouraged by Biomarker Progress
This article was originally published in RPM Report
It's been just over a year since the Food & Drug Administration started down the Critical Path to drug development reform, and senior agency staffers are already exuding confidence that at least one of its first showcase projects will be a winner.
You may also be interested in...
FDA is adopting a broad range of procedural changes in response to suggestions from outside critics to address drug safety issues. The most significant change, however, may be just a new state of mind.
FDA official David Graham went on Capitol Hill to discuss his view of what's wrong with the drug safety review process. He gained acclaim during the Vioxx aftermath, and proved he still has an avid following in Congress.
The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.